Can Seaport’s GlyphAgo overcome agomelatine’s liver problem? New Phase 1 data sharpen the test
Seaport's GlyphAgo shows 6.8-fold higher bioavailability as anxiety trials advance, but its potential to reduce liver risks remains unproven.
Pharma & Biotech
Pharma & Biotech
GlyphAgo boosted drug bioavailability 6.8-fold. Can Seaport solve agomelatine’s liver safety challenge?
Seaport's GlyphAgo improved agomelatine exposure in Phase 1. New Phase 2 trials will test efficacy, liver safety and anxiety outcomes.
Pharma & Biotech
Could deupirfenidone beat an approved IPF drug? Celea starts the Phase 3 test that will decide
Celea Therapeutics has begun an unusually ambitious Phase 3 program designed to prove that deupirfenidone is superior, rather than merely comparable, to the established antifibrotic pirfenidone. The approximately 1,100-patient trial could support a United States registration application if successful, but its 2029 readout leaves the company facing a long development period and an increasingly competitive
Pharma & Biotech
Seaport Therapeutics’ Glyph platform faces its real test as GlyphAllo advances in depression
Seaport Therapeutics’ GlyphAllo data sharpen the case for oral neuroactive steroids in depression. Read what this could change next.